ViGenCell Inc.
KOSDAQ-listed biotech venture developing cell therapies including ViTier for lymphoma and ViMedier for graft-versus-host disease.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2013 and listed on KOSDAQ in 2021, ViGenCell is a biotech venture specializing in immune cell therapies. Its pipeline includes ViTier (VT-EBV-N) for lymphoma, EiNK (VC-302, VC-420) for glioblastoma and hepatocellular carcinoma, and ViMedier (VM-GD) for graft-versus-host disease. VT-EBV-N has completed Phase 2 trials and is preparing for conditional approval, while VC-302, VC-420, and VM-GD remain preclinical, with VM-GD having standardized and patented an improved culture method; as of fiscal year 2023 (11th term), other merchandise accounted for 258 (92.7% of revenue), with no product revenue yet from cell therapies.
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2019 / 5 Korean MFDS device approvals · 2023–2024
- OrphanVT-EBV-N2019-10-04Orphan Drug designation · in development20190147316
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2024-10-08Product approval · Class 2체외 제인 24-915 호
- MFDSIVD reagents for pharmacogeneticsRevoked2024-09-30Product approval · Class 3체외 제허 24-661 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2024-08-16Product approval · Class 2체외 제인 24-784 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2023-02-13Product approval · Class 2체외 제인 23-4153 호
- MFDSIVD reagents for histocompatibility antigen, antibody not for transfusion or transplantation but for specific disease diagnosis, molecular diagnosticsRevoked2023-01-25Product approval · Class 2체외 제인 23-4087 호
Clinical trials
data.go.kr3 MFDS clinical trial authorisations · 2017–2020 (Phase 1/2a 1 · Phase 1 1 · Phase 2 1)
- Phase 1/2aVM-0012020-11-23
1 trial site
- Phase 1VT-Tri2020-09-21
7 trial sites
- Phase 2VT-EBV-N2017-12-26
12 trial sites
R&D and key agreements
Source: DART corporate disclosureViTier (VT-EBV-N) · NK/T세포 림프종 · 임상 2상 완료, 조건부 품목허가 준비 · Cell type: CTL (cytotoxic T lymphocyte), autologous
EiNK (VC-302) · 교모세포종 · 전임상 진행중 · Cell type: iPSC-derived NK cell, allogeneic/off-the-shelf
EiNK (VC-420) · 간세포암 · 전임상 진행중 · Cell type: iPSC-derived NK cell, allogeneic/off-the-shelf
ViMedier (VM-GD) · 이식편대숙주질환(GVHD) · 전임상 진행중 · Cell type: MDSC, allogeneic; improved culture method standardized and patented; preparing manufacturing site change to new in-house facility
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
Supplies synthetic genes (GenOligo) and DNA sequencing analysis services for biotech research.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition